J. Ayoub

发表

Systemic Treatment in Recurrent and Metastatic Unresectable Rectal Cancer

M. Tehfé, F. Otte, J. Ayoub, 2011 .

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

E. Eisenhauer, R. Wierzbicki, Y. Cormier, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.

J. Tabernero, M. Moore, F. Rivera, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, R. Feld, J. Maroun, 1988, British Journal of Cancer.

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, Y. Cormier, G. Goss, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.

R. Ginsberg, Y. Cormier, R. Feld, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.

D. Dunlop, J. von Pawel, U. Gatzemeier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

J. Tabernero, M. Moore, J. Maurel, 2014, The oncologist.

Delivery of anti-cancer drugs using microbubble-assisted ultrasound in digestive oncology: from preclinical to clinical studies

J. Escoffre, A. Bouakaz, S. Bodard, 2022, Expert opinion on drug delivery.

Tallimustine is inactive in patients with previously treated small cell lung cancer. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

F. Shepherd, Y. Cormier, W. Steward, 1996, Lung cancer.

Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.

F. Shepherd, L. Souhami, J. Viallet, 1994, Seminars in Oncology.

Is ultrasound lymph node examination superior to clinical examination in melanoma follow‐up? A monocentre cohort study of 373 patients

B. Giraudeau, L. Vaillant, L. Machet, 2005, The British journal of dermatology.

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

K. Gelmon, B. Leyland-Jones, P. Ghahramani, 2003 .

Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer.

R. Momparler, J. Ayoub, J. Ayoub, 2001, Lung cancer.

Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

K. Gelmon, B. Leyland-Jones, P. Ghahramani, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.